Antibiotic prophylaxis in COPD: Why, when, and for whom?

Area of Science:

• Pulmonary Medicine
• Infectious Disease

Background:

• Chronic obstructive pulmonary disease (COPD) treatment aims to prevent exacerbations.
• Standard therapies like bronchodilators and anti-inflammatories are insufficient for all infective exacerbations.
• Inhaled corticosteroids may increase bacterial load and pneumonia risk in some COPD patients.

Purpose of the Study:

• To evaluate the efficacy and risks of long-term or intermittent antibiotic treatment for COPD exacerbation prevention.
• To identify patient subgroups who may benefit from antibiotic therapy despite potential adverse effects.

Main Methods:

• Review of studies on macrolides and quinolones for long-term COPD management.
• Analysis of antibiotic effects on bacterial load and bronchial inflammation.
• Assessment of risks including adverse events and antibiotic resistance.

Main Results:

• Antibiotic therapy, particularly macrolides and quinolones, can reduce COPD exacerbations and hospitalizations.
• Benefits may stem from reduced airway bacterial load and/or inflammation.
• Long-term use carries risks of serious adverse events and bacterial resistance.

Conclusions:

• Long-term antibiotic therapy is a potential option for severe COPD patients with frequent exacerbations unresponsive to standard treatments.
• Treatment decisions require individualized risk-benefit assessment and careful clinical/microbiological monitoring.
• Optimal antibiotic choice, regimen, and duration require further research.